MSDC 0602

Drug Profile

MSDC 0602

Alternative Names: MSDC-0602; MSDC-0602K

Latest Information Update: 13 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Metabolic Solutions Development Company
  • Developer Cirius Therapeutics; Metabolic Solutions Development Company
  • Class Antihyperglycaemics; Insulin sensitisers; Small molecules; Thiazolidinediones
  • Mechanism of Action Mitochondrial protein stimulants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis
  • Preclinical Polycystic kidney disease
  • Suspended Type 2 diabetes mellitus

Most Recent Events

  • 11 Apr 2017 Octeta Therapeutics is now called Cirius Therapeutics
  • 01 Jul 2016 Phase-II clinical trials in Non-alcoholic steatohepatitis in USA (PO) (NCT02784444)
  • 18 May 2016 Cirius Therapeutics plans a phase II trial for Non-alcoholic fatty liver disease in USA (NCT02784444)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top